Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Organon & (OGN)

Organon Chief Commercial Officer Susanne Fiedler leaves role, to advise until April 30

Neutral Impact 3 of 5 leadership Written later

Organon & Co. said Susanne Fiedler ceased performing her duties as Chief Commercial Officer effective January 15, 2025. She will serve as a senior advisor until her departure, which is currently expected on or about April 30, 2025. The filing does not name a successor or describe any financial effect.

Key points

  • Susanne Fiedler ceased functioning as Chief Commercial Officer effective January 15, 2025.
  • Fiedler will serve as a senior advisor until her expected departure on or about April 30, 2025.
  • The filing does not name a replacement or describe compensation changes.

The filing

CompanyOrganon & (OGN)
Form8-K, current report
Filed with the SECJan 21, 2025, 7:01 AM ET
Accession number0001104659-25-004711

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.